UKRI CDT IN Biomedical AI w/ Julien Fauqueur

How BenevolentAI leverages ML and AI to develop life-changing medicines

Join Julien Fauqueur, Lead AI Scientist at BenevolentAI, for a  talk on how BenevolentAI combines AI with cutting edge science to de-risk drug discovery. Julien will give an introduction to BenevolentAI to the UKRI CDT Uni.Ed PhD students, and explore how we use machine learning and natural language processing to extract biomedical facts from literature, identify targets and, identify patient subgroups.

Register here →

Julien Fauqueur

Lead AI Scientist

As Lead AI scientist at BenevolentAI, Julien Fauqueur leads and develops novel NLP methods for Biomedical Information Extraction. He holds a PhD in Computer Science from INRIA (France). While a research associate at the University of Cambridge, then as as a researcher in industry, he delivered innovative products using computer vision and machine learning methods. His work was published in over 25 publications and led to 5 patents.

More Posts

You Might Also Like

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022